These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34292566)

  • 1. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Author's reply.
    Terlecki M; Wojciechowska W; Klocek M; Kania M; Małecki M; Grodzicki T; Rajzer M
    Kardiol Pol; 2021; 79(9):1050-1051. PubMed ID: 34292566
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?
    Patoulias D; Papadopoulos C; Kassimis G; Doumas M
    Kardiol Pol; 2021; 79(9):1048-1049. PubMed ID: 34292565
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Imprialos K; Stavropoulos K; Tranidou A; Karagiannis A; Doumas M
    Kardiol Pol; 2022; 80(1):80-82. PubMed ID: 34783355
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.
    Imprialos KP; Stavropoulos K; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):83-85. PubMed ID: 30009694
    [No Abstract]   [Full Text] [Related]  

  • 5. Author's Reply to Kuss and Rathmann's Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data".
    Gamble JM; Alkabbani W
    Drug Saf; 2023 May; 46(5):513-514. PubMed ID: 37060424
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to 'Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in subjects with heart failure?' Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'.
    De Biase N; Del Punta L; Pugliese NR
    Eur J Heart Fail; 2022 Feb; 24(2):401. PubMed ID: 34985799
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
    Koufakis T; Metallidis S; Zebekakis P; Ajjan RA; Kotsa K
    J Diabetes Sci Technol; 2020 Jul; 14(4):745-747. PubMed ID: 32486846
    [No Abstract]   [Full Text] [Related]  

  • 9. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.
    Soni S; Dyck JRB
    Can J Cardiol; 2020 Oct; 36(10):1691.e3. PubMed ID: 32717278
    [No Abstract]   [Full Text] [Related]  

  • 10. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?
    Chatterjee S
    Prim Care Diabetes; 2020 Oct; 14(5):564-565. PubMed ID: 32493609
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?
    Patoulias D; Papadopoulos C; Doumas M
    Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):547-549. PubMed ID: 36084991
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Metab Syndr; 2020; 14(4):347. PubMed ID: 32305776
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Crea F
    Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
    Khan MS; Fonarow GC; Greene SJ
    Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
    Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
    Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Petrie MC; Lee MMY; Docherty KF
    Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 18. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
    Crea F
    Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.